| Literature DB >> 19718302 |
Eduardo Ruiz1, Jorge Ferraris.
Abstract
The number of pediatric patients with end stage renal disease (ESRD) has been steadily growing during the last 10 years all over the world, because of the improvement of medical and surgical treatment of severe urologic malformations and congenital and acquired nephrological disorders. Kidney transplantation (Tx) with a live related donor continues to be the gold standard therapy to treat ESRD in children because of the best final results, the chronic lack of cadaveric donors and the frequent possibility of young patients to have parents or relatives as a source of a potential graft donor.Nowadays almost every pediatric patient can be dialyzed and transplanted, even early in life, if he or she has the possibility of a live related donor. Improvements in pediatric anesthesiology and intensive care have also been very important, in reducing the morbidity and mortality related to Tx procedures.Here we report our experience with Tx for the last 25 years, specially our long experience of live related donor transplantation in children and adolescents with emphasis on technical issues in small children and pediatric patients with severe urologic malformations and bladder dysfunction. We'll make special considerations on the improvement in short and long follow-up with the actual prevention and treatment of graft rejection, due to the new immunosuppressive agents and protocols.Entities:
Keywords: Kidney transplantation; live related donor; pediatric
Year: 2007 PMID: 19718302 PMCID: PMC2721578 DOI: 10.4103/0970-1591.36720
Source DB: PubMed Journal: Indian J Urol ISSN: 0970-1591
Comparison of Incidence of primary renal disease in three different groups of pediatric patients with renal transplantation
| Diagnosis | HIBA (1981–2006) % | Argentina (1990–2000) % | NAPRCTS 2006 % |
|---|---|---|---|
| Hemolytic uremic syndrome | 24.1 | 18.1 | 2.7 |
| Reflux and renal dysplasia | 17.5 | 15.6 | 21.2 |
| Obstructive uropathy/neurogenic bladder | 19.3 | 25.4 | 18.25 |
| Focal segmental glomeruloesclerosis | 6.9 | 13.2 | 11.7 |
| Renal cystic disease | 5.1 | n/a | 5.7 |
Changes in Immunosuppressive protocols and percentage of patients who presented episodes of acute rejection
| Period/drug | Azatioprine | Prednisone | Cyclosporine | MMF | Tacrolimus | Daclizumab | Thymoglobulin | Rejection (%) |
|---|---|---|---|---|---|---|---|---|
| 1979–1985 | X | X | O | O | O | O | O | 60 |
| 1986–1995 | X | X | X | O | O | O | O | 40 |
| 1995–1998 | O | X | X | X | O | O | O | 25 |
| 1999–2006 | O | X | O | X | X | X | X | 3 |
Only in cadaveric Tx,
since 2001
Figure 1a. bench repair of a small angiomyolipoma in the donor's kidney b. pyelo (p) uretero (u) anastomosis in a donor′s kidney with UPJO
Figure 2two vascular anastomosis in double renal donor′s artery to recipient's aorta
Figure 315 kg recipient, see the DPCA cannula on the right subcostal region, the vesicostomy and the wide hockey stick incision with a depression on the middle secondary to a scar because of a intrauterine vesicoamniotic shunt
Figure 4a. donor's ureter reimplanted on recipient's bladder (white arrow) b. ureterocystoplasty with all available folded ureter on the left side (black arrow)
Figure 5Double incision on a colonic patch of an augmented bladder, see the stripe of seromuscular tissue in the middle for improving donor ′s ureter backing